Principles of Translational Science in Medicine

From Bench to Bedside

Inbunden, Engelska, 2021

1 607 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt över 249 kr.

Beskrivning

Principles of Translational Science in Medicine: From Bench to Bedside, Third Edition, provides an update on major achievements in the translation of research into medically relevant results and therapeutics. The book presents a thorough discussion of biomarkers, early human trials, and networking models, and includes institutional and industrial support systems. It also covers algorithms that have influenced all major areas of biomedical research in recent years, resulting in an increasing number of new chemical/biological entities (NCEs or NBEs) as shown in FDA statistics.

New chapters include: Translation in Oncology, Biologicals, and Orphan Drugs. The book is ideal for use as a guide for biomedical scientists to establish a systematic approach to translational medicine and is written by worldwide experts in their respective fields.

Includes state-of-the-art principles, tools such as biomarkers and early clinical trials, algorithms of translational science in medicine
Provides in-depth description of special translational aspects in the currently most successful areas of clinical translation, namely oncology and immunology
Covers status of institutionalization of translational medicine, networking structures and outcomes at the level of marketing authorization

Produktinformation

Utgivningsdatum:2021-07-22
Mått:216 x 276 x 28 mm
Vikt:1 000 g
Format:Inbunden
Språk:Engelska
Antal sidor:494
Upplaga:3
Förlag:Elsevier Science
ISBN:9780128204931

Utforska kategorier

Farmakologi inom Medicin
Medicinsk utrustning och medicinska tekniker inom Medicin
Klinisk medicin och internmedicin inom Medicin

Mer om författaren

Martin Wehling is the Managing Director at the Institute of Experimental and Clinical Pharmacology and Toxicology. Martin Wehling is Director in Clinical Pharmacology at Mannheim Medical Faculty, Mannheim University of Heidelberg, Mannheim, Germany.

Innehållsförteckning

Part I: Introduction1. Introduction and definitions2. Problems, challenges, and initiatives in translationPart II. Target identification and validation3. “Omics translation: a challenge for laboratory medicine4. The power of genomics, metabolomics, and other omics for target identification and validation5. Potency analysis of cellular therapies: the role of molecular assays6. Translational pharmacogenetics: pharmacogenetically driven clinical decision making7. Tissue biobanks8. Animal models: value and translational potency9. Biomarkers in the context of health authorities and consortia10. Human studies as a source of target information11. Target profiling in terms of translatability and early translation planningPart III. Biomarkers as key elements of successful translation12. Biomarkers13. Genetics, molecular biomarkers, and artificial intelligence to improve diagnostic and prognostic efficacy14. Cardiovascular translational biomarkers: translational aspects of hypertension, atherosclerosis, and heart failure in drug development in the digital era15. Biomarkers in oncology16. Translational medicine in psychiatry: challenges and imaging biomarkersPart IV: Early clinical trial design17. Methodological studies18. The pharmaceutical research and development productivity crisis: can exploratory clinical studies be of any help?19. Adaptive trial design20. Combining regulatory and exploratory trials21. Accelerating proof of concept by smart early clinical trialsPart V: Toxicology in translation22. Pharmaceutical toxicology23. Translational safety medicinePart VI: Special topics in translation24. Cancer vaccines: translational strategies25. Translational aspects of biologicals: monoclonal antibodies and antibody-drug conjugates as examples26. Orphan drugs: why is translation so successful?Part VII: Biostatistics and modelling27. Translational science biostatistics28. Computational biology and model-based approaches in translational medicinePart VIII. Legal aspects and special interest groups29. Intellectual property and innovation in translational medicine30. Translational research in the fastest-growing population: older adultsPart IX. Integration and application of translational guidance31. Translational medicine: the changing role of big pharma32. Translational science in medicine: putting the pieces together-biomarkers, early human trials, networking, and translatability assessment33. Learning by experience